Browse News
Filter News
Found 142 articles
-
VBI Vaccines Reports Full Year 2023 Financial Results
4/16/2024
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2023.
-
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4/11/2024
VBI Vaccines Inc. announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 2,272,728 of its common shares and warrants to purchase up to 2,272,728 common shares, at an offering price of $0.88 per common share and associated warrant.
-
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4/9/2024
VBI Vaccines Inc. announced that it has entered into definitive agreements for the sale and issuance of 2,272,728 common shares of VBI at an offering price of $0.88 per common share, in a registered direct offering priced at-the-market under the Nasdaq rules.
-
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
4/3/2024
VBI Vaccines Inc. today announced that David E. Anderson, Ph.D., VBI’s Chief Scientific Officer, will present early tumor response data from the ongoing Phase 2b study of VBI-1901, VBI’s cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (rGBM) at the World Vaccine Congress Washington at 1:10pm ET on April 3, 2024.
-
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
4/2/2024
VBI Vaccines and the Canadian government broaden scope of longstanding collaboration to accelerate development of VBI’s novel, mRNA-launched enveloped virus-like particle vaccine (“MLE”) technology platform.
-
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
3/22/2024
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today provided a corporate update and reported its financial results for the year ended December 31, 2023.
-
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer
3/18/2024
Everest Medicines announced that the company has strengthened its management team with the appointments of Ms. Sandra Zeng as Chief Medical Officer and Mr. Rico Liang as Chief Product Officer.
-
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2/22/2024
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
-
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
2/14/2024
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences.
-
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
2/13/2024
Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK) today announced that it has entered into agreements with VBI Vaccines, Inc. ("VBI", NASDAQ: VBIV), ensuring expansion and control of future clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio's HBV functional cure portfolio.
-
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
1/3/2024
Brii Biosciences Limited, a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, is pleased to announce the appointment of Dr. Brian Alvin Johns, Ph.D., as Chief Scientific Officer, effective January 3, 2024.
-
VBI Vaccines Reports Third Quarter 2023 Financial Results
11/14/2023
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended September 30, 2023.
-
Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023
11/13/2023
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today shared three posters at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® in Boston, MA.
-
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
11/8/2023
Vir Biotechnology, Inc. announced it ranked first for the second year in a row on the 2023 Deloitte Technology Fast 500™, a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America.
-
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
11/2/2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.
-
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
10/11/2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight abstracts highlighting new data from its chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) clinical programs have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® , taking place in Boston, MA, from November 10-14, 2023.
-
VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
9/6/2023
VBI Vaccines Inc. announced topline cohort-level unblinded Week 36 data from interim analysis of a randomized, placebo-controlled and double-blinded Phase 2 study of BRII-179 (VBI-2601), a first-in-class Pre-S1/Pre-S2/S therapeutic vaccine, in combination treatment with pegylated interferon-alpha (PEG-IFNα) in chronic hepatitis B virus (HBV) patients compared with PEG-IFNα only treatment.
-
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B
9/6/2023
Brii Biosciences Limited announced topline cohort-level unblinded Week 24 and Week 36 data from interim analysis of a randomized, placebo-controlled and double-blinded Phase 2 study of BRII-179, a first-in-class Pre-S1/Pre-S2/S therapeutic vaccine, in combination treatment with pegylated interferon-alpha in patients with chronic hepatitis B compared with PEG-IFNα only treatment.
-
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
8/22/2023
Brii Biosciences Limited ("Brii Bio," "we," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced a corporate update and reported its interim results for the first six months ended June 30, 2023.
-
VBI Vaccines Reports Second Quarter 2023 Financial Results
8/14/2023
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended June 30, 2023.